Hormonal and metabolic status of patients with luminal and non-luminal variants of breast cancer
PDF (Русский)

Keywords

рак молочной железы
гетерогенность
подтипы
гормональные факторы

How to Cite

, , , , , & . (2014). Hormonal and metabolic status of patients with luminal and non-luminal variants of breast cancer. Voprosy Onkologii, 60(6), 745–749. https://doi.org/10.37469/0507-3758-2014-60-6-745-749

Abstract

The heterogeneous nature of breast cancer (BC), based according to modern concepts, on the existence of individual molecular biological subtypes of the disease causes the need to analyze this problem on the basis of different clinical and laboratory approaches. Study of hormonal and metabolic status of BC patients with different subtypes was performed up to now infrequently and had not yet resulted in any preconceived idea. In this paper we examined a representative group of patients who were divided, mainly on immunohistochemical analysis of tumor material, into groups with luminal A, luminal B, thrice-negative and HER2-positive variant of BC. It was found that a subgroup of luminal B patients was characterized by lowest weight and the lowest content of total and visceral fat in the body. The highest values of these four indicators were peculiar to thrice-negative BC patients with significant difference from patients with luminal B form. It was essential that no differences between comparative groups by levels of insulinemia, glycemia and lipidemia were identified. In comparative evaluation of parameters of reproductive and thyroid function to attempt to detect differences between subgroups also failed to find. In the meantime it was important to pay attention to the fact that the differences between the thrice-negative form of the disease and a process with enhanced expression of HER-2 or between the luminal forms A and B were greater than between united luminal and non-luminal patient’s groups that is significant for future applied studies.
https://doi.org/10.37469/0507-3758-2014-60-6-745-749
PDF (Русский)

References

Берштейн Л.М. Эндокринология рака молочной железы как гетерогенного заболевания: десятилетие после Миллениума // Вопр. онкол. - 2013. -T. 59 (3). - С. 292-298.

Берштейн Л.М., Семиглазов В.Ф. Подтипы рака молочной железы и их гормонально - метаболическое «обеспечение»: прикладной аспект // Вопр. онкол. - 2011. - Т. 57 (5). - С. 559-566.

Семиглазов В.Ф. Планирование лечения рака молочной железы в зависимости от биологического подтипа // Вопр. онкол. 2014. - Т. 60 (4). - С. 529-530.

Семиглазов В.Ф., Семиглазов В.В., Дашян Г.А. Общие стандарты лечения рака молочной железы, основанные на определении биологических подтипов. М., 2011. - 82 с.

Семиглазов В.Ф., Семиглазов В.В., Нургазиев К.Ш. Обоснование стандартов лечения рака молочной железы. Алматы, 2007. - 364 с.

Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations // Ann Oncol. - 2012. - Vol. 23 (Suppl 6). - P. vi7-vi12.

Colonna S.V., Douglas Case L., Lawrence J.A. A retrospective review of the metabolic syndrome in women diagnosed with breast cancer and correlation with estrogen receptor // Breast Cancer Res Treat. - 2012. - Vol. 131 (1). - P. 325-331.

Davis A.A., Kaklamani V.G. Metabolic syndrome and triple-negative breast cancer: a new paradigm // Int J. Breast Cancer. - 2012: 809291.

De Sibio M.T., de Oliveira M., Moretto F.C. et al. Triiodothyronine and breast cancer // World J. Clin Oncol. - 2014. - Vol. 5 (3). - P. 503-508.

Fisher B. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century // Eur J. Cancer. - 1999. - Vol. 35 (14). - P. 1963-1973.

Hefti M.M., Hu R., Knoblauch N.W. et al. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype // Breast Cancer Res. - 2013/ - Vol. 15. - R 68.

James R.E., Lukanova A., Dossus L. et al. Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study // Cancer Prev Res (Phila) - 2011. - Vol. 4 (10). - P. 1626-1635.

Key T.J. Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids. - 2011. - Vol. 76 (8). - P. 812-815.

Kwan M.L., Kushi L.H., Weltzien E. et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors // Breast Cancer Res. 2009. - Vol. 11 (3). - P. 31.

Matthews D.R., Hosker J.P., Rudenski A.S. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man // Diabetologia. - 1985. - Vol. 28 (7). - P. 412-419.

Munsell M.F., Sprague B.L., Berry D.A. et al. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status // Epidemiol Rev. - 2014. - Vol. 36 (1). - P. 114-136.

Perou C.M., Børresen-Dale A.L. Systems biology and genomics of breast cancer // Cold Spring Harb Perspect Biol. - 2011. - Vol. 3 (2). - P. 1-9.

Perou C.M., Parker J.S., Prat A. et al. Clinical implementation of the intrinsic subtypes of breast cancer // Lancet Oncol. - 2010. - Vol. 11 (8). - P. 718-719.

Phipps A.I., Malone K.E., Porter P.L. et al. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women // Cancer Epidemiol Biomarkers Prev. - 2008. - Vol. 17. - P. 2078-2086.

Roberson L.L., Aneni E.C., Maziak W. et al. Beyond BMI: The «Metabolically healthy obese» phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality -- a systematic review // BMC Public Health - 2014. - Vol. 14. - P. 14.

Yersal O., Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications // World J Clin Oncol. 2014 Aug 10; 5 (3): 412-424.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...